tirzepatide or mounjaro which is better Compounded vs Mounjaro/Zepbound: 75% Cheaper Mounjaro and Zepbound Are No

The Role of Patient Monitoring To address these cardiovascular risks, close and consistent monitoring is essential

Accessed May 6, 2020

The primary focus was on GLP-1 agonists, including semaglutide and liraglutide, while a secondary focus was placed on officially approved alcohol use disorder medications, such as naltrexone, disulfiram, and acamprosate

As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)